Interpore Cross and Biomet to Merge

(Irvine, CA, USA) with Biomet, Inc. (Warsaw, IN, USA). Interpore Cross stockholders will receive U.S.$14.50 in cash in exchange for each share of common stock they own, representing a total equity value of about $280 million.

Biomet designs and manufactures products used by musculoskeletal medical specialists in both surgical and nonsurgical therapy, such as orthopedic support devices, general surgery instruments, spinal implants, and bone substitute materials. The company's products are distributed in more than 100 countries.

Interpore Cross is focused on providing innovative products for spinal surgery. Its three major product groups are spinal implants, orthobiologic products, and minimally invasive surgery products. "We're pleased the transaction is complete and we can now focus on the integration plan with Biomet,” said David Mercer, CEO of Interpore Cross.



Related Links:
Biomet
Interpore Cross